

Stanford



Marisa Holubar

Clinical Associate Professor, Medicine - Infectious Diseases

CLINICAL OFFICES

- **Infectious Diseases**

300 Pasteur Dr Rm L134

Stanford, CA 94305

Tel

Fax

Bio

BIO

Dr. Marisa Holubar specializes in the treatment of infectious diseases and works primarily in the inpatient setting. She is particularly interested in antimicrobial stewardship and hospital epidemiology.

CLINICAL FOCUS

- Infectious Disease

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Infectious Diseases

ADMINISTRATIVE APPOINTMENTS

- Associate Medical Director, Stanford Antimicrobial Safety and Sustainability Program, (2015- present)
- Associate Medical Director, Infection Prevention, Stanford Hospital and Clinics, (2015- present)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Physician, California Department of Public Health Healthcare Associated Infections Advisory Committee (2016 - present)

PROFESSIONAL EDUCATION

- Fellowship: Stanford University School of Medicine Registrar (2013) CA
- Board Certification: Infectious Disease, American Board of Internal Medicine (2012)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2009)
- Residency: Brown University (2009) RI
- Medical Education: University of Wisconsin School of Medicine (2005) WI
- Masters, Stanford University , Epidemiology and Clinical Research (2014)

LINKS

- Stanford Antimicrobial Safety and Sustainability Program: <http://med.stanford.edu/bugsanddrugs.html>

- Online course - Antimicrobial Stewardship: <https://med.stanford.edu/cme/courses/online/optimizing-antimicrobial-therapy.html>
- <https://openwho.org/courses/AMR-competency>: <https://openwho.org/courses/AMR-competency>

Publications

PUBLICATIONS

- **Oral Fluoroquinolone or Trimethoprim-sulfamethoxazole vs. SS-lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis.** *Open forum infectious diseases*
Punjabi, C., Tien, V., Meng, L., Deresinski, S., Holubar, M.
2019
- **Conversion from Vancomycin Trough Concentration-Guided Dosing to Area Under the Curve-Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center** *PHARMACOTHERAPY*
Meng, L., Wong, T., Huang, S., Mui, E., Nguyen, V., Espinosa, G., Desai, J., Holubar, M., Deresinski, S.
2019; 39 (4): 433–42
- **Conversion from Vancomycin Trough Concentration-Guided Dosing to Area Under the Curve-Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center.** *Pharmacotherapy*
Meng, L., Wong, T., Huang, S., Mui, E., Nguyen, V., Espinosa, G., Desai, J., Holubar, M., Deresinski, S.
2019
- **Antimicrobial Resistance: A global public health emergency further exacerbated by international travel.** *Journal of travel medicine*
Holubar, M.
2019
- **Antimicrobial Resistance in Sexually Transmitted Infections.** *Journal of travel medicine*
Tien, V., Punjabi, C., Holubar, M. K.
2019
- **Comprehensive Guidance for Antibiotic Dosing in Obese Adults** *PHARMACOTHERAPY*
Meng, L., Mui, E., Holubar, M. K., Deresinski, S. C.
2017; 37 (11): 1415–31
- **Feasibility and applicability of antimicrobial stewardship in immunocompromised patients.** *Current opinion in infectious diseases*
Robilotti, E., Holubar, M., Seo, S. K., Deresinski, S.
2017
- **Educating front-line clinicians about antimicrobial resistance** *LANCET INFECTIOUS DISEASES*
Robilotti, E., Holubar, M., Nahrgang, S., van de Sande-Bruinsma, N., Wong, D., Deresinski, S.
2017; 17 (3): 257–58
- **A high value care curriculum for interns: a description of curricular design, implementation and housestaff feedback.** *Postgraduate medical journal*
Hom, J., Kumar, A., Evans, K. H., Svec, D., Richman, I., Fang, D., Smeraglio, A., Holubar, M., Johnson, T., Shah, N., Renault, C., Ahuja, N., Witteles, et al
2017
- **Bacteremia due to Methicillin-Resistant Staphylococcus aureus New Therapeutic Approaches** *INFECTIOUS DISEASE CLINICS OF NORTH AMERICA*
Holubar, M., Meng, L., Deresinski, S.
2016; 30 (2): 491-?
- **Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia?** *Antimicrobial agents and chemotherapy*
Kalil, A. C., Holubar, M., Deresinski, S., Chambers, H. F.
2019; 63 (11)
- **Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia?** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*
Kalil, A. C., Holubar, M., Deresinski, S., Chambers, H. F.
2019; 63 (11)

- **Antimicrobial resistance in methicillin-resistant *Staphylococcus aureus* to newer antimicrobial agents.** *Antimicrobial agents and chemotherapy*
Watkins, R. R., Holubar, M., David, M. Z.
2019
- **Dual reporting of *Clostridioides difficile* PCR and predicted toxin result based on PCR cycle threshold reduces treatment of toxin-negative patients without increases in adverse outcomes.** *Journal of clinical microbiology*
Hitchcock, M. M., Holubar, M., Hogan, C. A., Tompkins, L. S., Banaei, N.
2019
- **Protocol Paper: Oral Poliovirus Vaccine Transmissibility in Communities After Cessation of Routine Oral Poliovirus Vaccine Immunization** *CLINICAL INFECTIOUS DISEASES*
Sarnquist, C., Holubar, M., Garcia-Garcia, L., Ferreyra-Reyes, L., Delgado-Sanchez, G., Pablo Cruz-Hervert, L., Montero-Campos, R., Altamirano, J., Purington, N., Boyle, S., Modlin, J., Ferreira-Guerrero, E., Canizales-Quintero, et al
2018; 67: S115–S120
- **Lab Protocol Paper: Use of a High-throughput, Multiplex Reverse-transcription Quantitative Polymerase Chain Reaction Assay for Detection of Sabin Oral Polio Vaccine in Fecal Samples** *CLINICAL INFECTIOUS DISEASES*
van Hoorebeke, C., Huang, C., Leary, S., Holubar, M., Altamirano, J., Halpern, M. S., Sommer, M., Maldonado, Y.
2018; 67: S121–S126
- **Characterization of Household and Community Shedding and Transmission of Oral Polio Vaccine in Mexican Communities With Varying Vaccination Coverage** *CLINICAL INFECTIOUS DISEASES*
Altamirano, J., Purington, N., Behl, R., Sarnquist, C., Holubar, M., Garcia-Garcia, L., Ferreyra-Reyes, L., Montero-Campos, R., Pablo Cruz-Hervert, L., Boyle, S., Modlin, J., van Hoorebeke, C., Leary, et al
2018; 67: S4–S17
- **Deep Sequencing Prompts the Modification of a Real-time RT-PCR for the Serotype-Specific Detection of Polioviruses.** *Journal of virological methods*
Holubar, M., Sahoo, M. K., Huang, C., Mohamed-Hadley, A., Liu, Y., Waggoner, J. J., Troy, S. B., Garcia-Garcia, L., Ferreyra-Reyes, L., Maldonado, Y., Pinsky, B. A.
2018
- **Protocol Paper: Oral Poliovirus Vaccine Transmissibility in Communities After Cessation of Routine Oral Poliovirus Vaccine Immunization.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*
Sarnquist, C., Holubar, M., Garcia-Garcia, L., Ferreyra-Reyes, L., Delgado-Sanchez, G., Cruz-Hervert, L. P., Montero-Campos, R., Altamirano, J., Purington, N., Boyle, S., Modlin, J., Ferreira-Guerrero, E., Canizales-Quintero, et al
2018; 67 (suppl_1): S115–S120
- **Lab Protocol Paper: Use of a High-throughput, Multiplex Reverse-transcription Quantitative Polymerase Chain Reaction Assay for Detection of Sabin Oral Polio Vaccine in Fecal Samples.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*
van Hoorebeke, C., Huang, C., Leary, S., Holubar, M., Altamirano, J., Halpern, M. S., Sommer, M., Maldonado, Y.
2018; 67 (suppl_1): S121–S126
- **Characterization of Household and Community Shedding and Transmission of Oral Polio Vaccine in Mexican Communities With Varying Vaccination Coverage.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*
Altamirano, J., Purington, N., Behl, R., Sarnquist, C., Holubar, M., Garcia-Garcia, L., Ferreyra-Reyes, L., Montero-Campos, R., Cruz-Hervert, L. P., Boyle, S., Modlin, J., van Hoorebeke, C., Leary, et al
2018; 67 (suppl_1): S4–S17
- **Assessing the individual risk of fecal poliovirus shedding among vaccinated and non-vaccinated subjects following national health weeks in Mexico** *PLOS ONE*
Ferreyra-Reyes, L., Pablo Cruz-Hervert, L., Troy, S. B., Huang, C., Sarnquist, C., Delgado-Sanchez, G., Canizales-Quintero, S., Holubar, M., Ferreira-Guerrero, E., Montero-Campos, R., Rodriguez-Alvarez, M., Mongua-Rodriguez, N., Maldonado, et al
2017; 12 (10): e0185594
- **Detection of Emerging Vaccine-Related Polioviruses by Deep Sequencing.** *Journal of clinical microbiology*
Sahoo, M. K., Holubar, M., Huang, C., Mohamed-Hadley, A., Liu, Y., Waggoner, J. J., Troy, S. B., Garcia-Garcia, L., Ferreyra-Reyes, L., Maldonado, Y., Pinsky, B. A.
2017
- **Infection Rates.** *Journal of clinical microbiology*
Truong, C. Y., Gombar, S., Wilson, R., Sundararajan, G., Tekic, N., Holubar, M., Shepard, J., Madison, A., Tompkins, L., Shah, N., Deresinski, S., Schroeder, L. F., Banaei, et al

2017

- **Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis.** *PloS one*
Holubar, M., Stavroulakis, M. C., Maldonado, Y., Ioannidis, J. P., Contopoulos-Ioannidis, D.
2017; 12 (3)
- **Shedding of Oral Poliovirus Vaccine (OPV) by HIV-Infected and -Uninfected Mothers of OPV-Vaccinated Zimbabwean Infants.** *Journal of the Pediatric Infectious Diseases Society*
Holubar, M., Troy, S. B., Nathoo, K., Stranix-Chibanda, L., Musingwini, G., Srinivas, N., Huang, C., Junn, A., Halpern, M. S., Maldonado, Y. A.
2016
- **Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: A systematic review and implications for polio eradication** *VACCINE*
Guo, J., Bolivar-Wagers, S., Srinivas, N., Holubar, M., Maldonado, Y.
2015; 33 (10): 1235-1242
- **Community circulation patterns of oral polio vaccine serotypes 1, 2, and 3 after mexican national immunization weeks.** *journal of infectious diseases*
Troy, S. B., Ferreyra-Reyes, L., Huang, C., Sarnquist, C., Canizales-Quintero, S., Nelson, C., Báez-Saldaña, R., Holubar, M., Ferreira-Guerrero, E., García-García, L., Maldonado, Y. A.
2014; 209 (11): 1693-1699
- **Incident Hepatitis C Virus Infection among US HIV-Infected Men Enrolled in Clinical Trials** *CLINICAL INFECTIOUS DISEASES*
Taylor, L. E., Holubar, M., Wu, K., Bosch, R. J., Wyles, D. L., Davis, J. A., Mayer, K. H., Sherman, K. E., Tashima, K. T.
2011; 52 (6): 812-818